RESUMO
Hematopoietic stem cell transplantation (HSCT) recipients may infrequently develop parasitic infections at the time of the procedure via contamination from allograft tissue or blood products, and in the post-transplantation period through the traditional route of infection or as a reactivation caused by immunosuppression related to the transplant. To reduce risk, efforts should be directed at performing a comprehensive history, maintaining a high index of suspicion, and adhering to preventive measures. Additional strategies for the prevention, screening and careful follow-up, identification, and pre-emptive treatment of parasitic infections are required to reduce morbidity and mortality in HSCT patients.
Assuntos
Neoplasias Hematológicas/complicações , Neoplasias Hematológicas/parasitologia , Transplante de Células-Tronco Hematopoéticas/efeitos adversos , Doenças Parasitárias/etiologia , Estrongiloidíase/etiologia , Toxoplasmose/etiologia , Humanos , Terapia de Imunossupressão/efeitos adversos , Doenças Parasitárias/tratamento farmacológico , Doenças Parasitárias/transmissão , Estrongiloidíase/tratamento farmacológico , Toxoplasmose/tratamento farmacológicoAssuntos
Doenças Endêmicas , Neoplasias Hematológicas/terapia , Transplante de Células-Tronco Hematopoéticas , Toxoplasma , Toxoplasmose , Adulto , Idoso , Aloenxertos , Brasil , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Toxoplasmose/diagnóstico , Toxoplasmose/etiologia , Toxoplasmose/terapiaRESUMO
Viral infections have been reported with dasatinib use, but its cytomegalovirus risk after hematopoietic-cell transplantation (HCT) is not known. We found that post-HCT dasatinib use increased the risk of cytomegalovirus reactivation (adjusted hazard ratio, 7.65; 95% confidence interval, 1.84-31.7), controlling for acute graft-versus-host disease, in 109 patients with Philadelphia-chromosome-positive malignancies.